Painful Diabetic Neuropathy Drugs market: Global Market Size, Industry Share, Trends and Forecast 2026

The Painful Diabetic Neuropathy Drugs market wealth was US$ 4,811.8 Mn in 2017, and will reach US$ 8,962.0 Mn 2026, with a CAGR of 6.6 % during 2018-2026. Based on the Painful Diabetic Neuropathy Drugs industrial chain, this report mainly refines the definition, types, applications and major players of Painful Diabetic Neuropathy Drugs market in details. Wide analysis about market status (2018-2026), advantages and disadvantages of enterprise Products, regional industrial layout characteristics and macroeconomic policies, enterprise competition pattern, industry development trends (2018-2026), industrial policy has also be included. From raw materials to downstream buyers of this industry will be explained accurately, the feature of product circulation and sales channel will be shown as well. In a word, this report will help you to establish a panorama of industrial development and characteristics of the Painful Diabetic Neuropathy Drugs market.

Get Sample:

Browse Full Report:

Market Insights

Global painful diabetic neuropathy drugs (PDN) market accounted to a market value of US$ 4,811.8 Mn in 2017 and projected to attain value of US$ 8,962.0 Mn by 2026 at a CAGR of 6.6% during the forecast period. The growth of this market primarily driven by the ever-growing pool of geriatric population with diabetes. The rise in availability of suitable treatment options and the growing awareness on PDN catalyzes the demand for PDN drugs. With only four drugs currently approved for the management of PDN (Lyrica, Cymbalta, Nucynta and Qutenza), there arises a huge opportunity for new and emerging market players with potential pipeline portfolio. Of the marketed products analyzed, Lyrica accounted for a maximum market share in 2017 and will continue similar trend through 2026. The recent approval of Lyrica’s control release formulation in October 2017 further augments its market growth. The PDN drugs market observes a presence of strong pipeline portfolio, which would facilitate the overall growth during the forecast period from 2018 to 2026. ViroMed Co. Ltd.’s VM202 currently in phase III is the only gene therapy developed with disease modifying properties. However, the higher pricing of gene therapy could hamper the growth of VM202 in the near future.

Major Players in Heading Indicators market are:

Other players with potential product portfolio includes Pfizer, Inc., Grunenthal GmbH, Daiichi-Sankyo Company Limited, ViroMed Co. Ltd., Collegium Pharmaceutical, Inc., Acorda Therapeutics, Inc., Zydus Pharmaceuticals USA, Inc., Mallinckrodt, Inc., and Macleods Pharmaceuticals Ltd.

Regions play vital role in Heading Indicators market are:

  • North America
    • United States
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • Rest of Middle East & Africa

Browse Full Report:

Related posts

Leave a Comment